As of market close on Friday, Jan. 24, Moderna stock is up 21.6% this week. Here's why.

Based on its share price, down 75% in the last three years, it's easy to write off Moderna (NASDAQ: MRNA) as a biotech ...

Moderna wins EU tender to supply COVID-19 vaccines for up to four years, offering diverse formats like prefilled syringes to ...

Last Friday, HHS announced it will provide approximately $590 million to Moderna to accelerate the development of mRNA-based ...

The Agreement provides participating countries with the opportunity to diversify their mRNA COVID-19 vaccine supply and gain access to pre-filled ...

No person-to-person spread has been detected, but that doesn’t mean an H5N1 avian influenza pandemic isn’t possible or even ...

In this review of RNA therapies, we paint an overview of what’s going on in a field that is addressing a number of diseases.

As Moderna (NASDAQ: MRNA) looks to shore up its business in the wake of its declining coronavirus vaccine sales, it's natural for investors to wonder about where the biotech will go in the near future ...

RNA vaccine developer Moderna (MRNA) is climbing nearly 5% in early trading today after it was awarded about $590 million by the U.S.

Moderna, Inc. (NASDAQ:MRNA) today announced ongoing support from the U.S. Department of Health and Human Services (HHS) to accelerate the development of mRNA-based pandemic influenza vaccines. The ...

Merck shares trade at a significant discount to peers. The company faces challenges, but there are reasons to be bullish.

HHS Allocates $590 Million to Speed Up the Development of mRNA Vaccines for Pandemic Influenza, Including an H5N1 (Bird Flu) Vaccine ...